Creating organoids from colorectal tumors and liver metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot feasibility study focuses on developing organoids from primary colorectal tumors and their synchronous liver metastases. The organoids will be utilized to investigate the function of genes influenced by the NF-Y/p53 complex through gene overexpression and silencing. Functional assays will be conducted to assess proliferation, invasion, and motility, as well as interactions with patient-derived immune cells. The goal is to identify new therapeutic pathways for targeted therapy and immunotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients \> 18 years
* Histological and cytological diagnosis of colorectal cancer neoplasia that has developed a liver metastasis
* Patients who are candidates for surgery for colorectal cancer with liver metastasis
* Signing of the relevant informed consent form.

Exclusion Criteria:

* All exclusion criteria adopted in surgical protocols will be applied to the study

Where it's running

• "Regina Elena" National Cancer Institute
  Rome, Italy Recruiting

Study contacts

• Principal investigator: Giulia Piaggio, Biologist — IRCCS National Cancer Institute
• Study coordinator: Giulia Piaggio, Biologist
• Email: gialia.piaggio@ifo.it
• Phone: +39 0652662458

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prehabilitation before high-risk cancer surgery

  This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07638410

• Personal cancer risk testing using genetic, blood, and tumor monitoring

  This project will test whether combining genetic testing, blood-based analyses, and tumor tissue checks can identify personal cancer risk and detect early recurrence in adults with breast, ovarian, colorectal, melanoma, or certain non-small cell lung cancers.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Turin · NCT07469709

• Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease

  This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.

  Recruiting San Raffaele University · Milan, Lombardy and 3 other locations · NCT07450612

• Colorectal Cancer Screening Outreach for Better Adherence

  This trial tests a bundled messaging approach to help adults at risk complete colorectal cancer screening.

  Recruiting Yale University · New Haven, Connecticut · NCT07345676

• Blood-based delta-HLD methylation test for detecting colorectal cancer

  This will try a blood-based delta-HLD methylation test to see if it can detect colorectal cancer in people scheduled for colonoscopy or colorectal surgery.

  Recruiting Epiliquid Holding, Inc · Mendoza · NCT07148297

• MBRC-201 dose-finding and safety in advanced metastatic solid tumors

  We will test different doses of an antibody-drug conjugate called MBRC-201 in adults whose advanced metastatic cancers (including prostate, breast, colorectal, lung, and pancreatic cancer) have not responded to standard treatments.

  Recruiting at 7 sites Phase 1/2 MBrace Therapeutics · San Francisco, California and 6 other locations · NCT07145255

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.